**Verastem Inc. (VSTM) shares surged 6.3% to close at $5.40 on [specific date needed]**, driven by above-average trading volume and renewed investor confidence in its growth prospects. The company’s marketed product, Avmapki Fakzynja Co-Pack (avutometinib capsules and defactinib tablets), is approved in the U.S. for treating KRAS mutant recurrent low-grade serous ovarian cancer, contributing to a 35.1% gain over the past month.
**For its upcoming quarterly report, Verastem is expected to post a loss of $0.46 per share**, reflecting an 18% decline year-over-year. Revenue projections stand at $23.15 million, marking a staggering 981.8% increase from the previous year. However, earnings estimate revisions have trended 4.8% lower over the last month, which historically correlates with limited stock price appreciation.
**Verastem currently holds a Zacks Rank of #3 (Hold)**, indicating a neutral outlook. In the same industry, Acadia Pharmaceuticals (ACAD) closed 1.6% higher at $26.41 and is also rated #3.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
